Vancouver, Canada – January 28, 2025 – The Spondylitis Association of America (SAA) invited Dr. Walter Maksymowych to join their latest episode of Spondycast, where he discusses the growing role of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) in the diagnosis and management of axial spondyloarthritis.
Dr. Maksymowych, a leading expert in rheumatology and biomarker research, shares insights on how biomarker-based testing is helping clinicians better detect and manage axSpA—a condition that can often be difficult to diagnose in its early stages.
In the Spondycast episode, Dr. Maksymowych highlights:
- The significance of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) in axSpA
- How biomarker testing could improve early diagnosis and disease management
- The potential impact of biomarker-driven approaches on personalized treatment strategies
These insights the role of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) as an exciting advancement in biomarker research, and how this novel biomarker has the potential to transform the way axSpA is diagnosed and managed.
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3eta protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs expand Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.
Media Contact
Nima Mazinani
604-674-8231
[email protected]